Mai Capital Management Ocuphire Pharma, Inc. Transaction History

Mai Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$1.89 - $3.27 $317,380 - $549,118	-167,926 Reduced 42.85%	223,970 $450,000
Q4 2023 Feb 09, 2024	SELL	$2.59 - $3.64 $165,192 - $232,162	-63,781 Reduced 14.0%	391,896 $1.18 Million
Q3 2023 Nov 14, 2023	SELL	$3.35 - $4.33 $98,392 - $127,176	-29,371 Reduced 6.06%	455,677 $1.53 Million
Q2 2023 Aug 02, 2023	SELL	$3.63 - $6.38 $35,000 - $61,515	-9,642 Reduced 1.95%	485,048 $2.11 Million
Q1 2023 May 10, 2023	BUY	$3.01 - $3.85 $164,403 - $210,283	54,619 Added 12.41%	494,690 $1.86 Million
Q4 2022 Feb 09, 2023	BUY	$2.04 - $3.53 $169,570 - $293,424	83,123 Added 23.29%	440,071 $1.55 Million
Q3 2022 Nov 15, 2022	BUY	$1.82 - $2.79 $649,645 - $995,884	356,948 New	356,948 $717,000

2.74M

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $26.5M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.